Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 February 2021 | Story Leonie Bolleurs | Photo Ané van der Merwe
Dr Ismari van der Merwe was instrumental in establishing the new Department of Sustainable Food Systems and Development.

Dr Ismari van der Merwe believes that by forging strong relationships, women can affect virtually every aspect of their students' lives, teaching them vital life lessons that will help them succeed beyond term papers and standardised tests. 

She states that it is not always easy to change a student's life, so it takes a great teacher to do so. “You, as a teacher, have a very significant, lifelong impact on all your students. This impact involves not only the teaching of particular academic skills, but as importantly, the fostering of student self-esteem.”

“Reinforcing self-esteem in the classroom is associated with increased motivation and learning,” she says.

Dr Van der Merwe is Lecturer and Programme Director in the Department of Sustainable Food Systems and Development at the University of the Free State (UFS).

On 11 February – International Day of Women and Girls in Science – the UFS is celebrating her not only for the impact she has on her students, but also for being instrumental in establishing the new Department of Sustainable Food Systems and Development, putting the UFS on the international forefront.

A sustainable food system

“We want our students to be part of a sustainable food system that provides healthy food that meets food needs, while maintaining healthy ecosystems that can also provide food for generations to come, with minimal negative impact to the environment,” she says. 

“The right to food is a fundamental human right.”

Dr Van der Merwe believes that a healthy personal food system and how it is managed is now more critical than ever before. 

Her current work involves managing the five main food-related values of taste, health, cost, time, and social relationships, as well as other less prominent values of symbolism, ethics, variety, safety, waste, and quality within these personal food systems. She feels the prominence of these values varies among us as well as across our eating situations. “More research on this will be fascinating,” says Dr Van der Merwe. 

A male-dominated field

On the role of women in science, Dr Van der Merwe says it is often considered a male-dominated field. “According to United Nations data, less than 30% of scientific researchers worldwide are women,” she states.

Telling her story about becoming a scientist, she says that science chose her. “Many scientists have reported that their interest and curiosity in science or the natural world started in early childhood.”

We want our students to be part of a sustainable food system that provides healthy food that meets food needs, while maintaining healthy ecosystems that can also provide food for generations to come, with minimal negative impact to the environment. – Dr Ismari van der Merwe

 

“I started as a teacher and ended up working for the Agricultural Research Council, where I was responsible for a research programme on dry beans and started a small-scale research factory.”

“Later when we moved to Bloemfontein, I joined the UFS. Here I am privileged to be able to do research and teach. Science chose me as part of my life journey, and I never looked back.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept